7% (22/33) P2-like prophage candidate positive Selleckchem BYL719 strains   2668a φ52237-like + + + + + + E0237 c φ52237-like + + + + + + E0394 φ52237-like + + + + + + 1026b d φ52237-like + + + + + + 708a φ52237-like e + + + + – + 2618a P2L-A + + + – - + 2661a P2L-A + + + – - + 2692a P2L-A + + + – - + 2717a P2L-A + + + – - + E0021 P2L-A + + + – - + E0235 P2L-A + + + – - + E0279 P2L-A + + + – - + E0345 P2L-A + + + – - + E0384 P2L-A + + + – - + E0386 P2L-A + + + – - + K96243 f P2L-A + + + – - + S13 g P2L-A + + + – - + 2698a P2L + + – - – - 2704a P2L h + + – - + – E0342 P2L + + – - – - E0366 P2L + + – - – - E0377 P2L + + – - – - 2613a   – - – - – ND i 2667a   – - – - – ND 2673a   – - – - – ND 2682a   – - -

– - ND 2769a   – - – - – ND E0016   – - – - – ND E0034   – - – - – ND E0241   – - MM-102 chemical structure – - – ND E0356   – - – - – ND E0411   – - – - – ND MSHR305   – - – - – ND Strains with low φX216 plaquing efficiency j 17. 4% (4/23), P2-like prophage candidate positive strains   2625a φ52237-like + + + + + + 2670a MK-0457 P2L-A + + + – - + E0037 P2L-A + + + – - + E0380 P2L-A + + + – - + 2637a   – - – - – ND 2650a   – - – - – ND 2660a   – - – - – ND 2685a   – - – - – ND 2708a   – - – - – ND 2719a   – - – - – ND 2764b

  – - – - – ND E0024   – - – - – ND E0031   – - – - – ND E0181   – - – - – ND E0371   – - – - – ND E0372   – - – - – ND E0378   – - – - – ND E0383   – - – - – ND E0393   – - – - – ND 1710a   – - – - – ND 1710b k   – - – - – - 1106b   – - – - – ND 406e   – - – - – ND Non-φX216 plaquing strains 25. 0% (4/16), P2-like prophage candidate positive strains   2671a P2L-A + + + – - + 2674a P2L-A + + + – - + 2677a P2L-A + + + – - + Pasteur 6068 P2L-A + + + – - + 2614a   – - – - – ND 2617a   – - – - – ND 2640a   – - – - – ND 2665a   – - – - – ND 2689b   – - – - – ND 2694a

  – - – - – ND E0008   – - – - – ND E0183   – - – - – ND E0350   – - – - – ND E0396   – - – - – ND 1106a   – - – - – ND MSHR668   – - – - – ND a φ52237-like assignment; positive PCR amplicons from multiplex probes P2-like 1, P2-like 2, P2-like Dolutegravir manufacturer group A, and individual PCR probes φX216 scrnA, φX216 scrnB and GI2. P2L-A assignment; positive PCR amplicons from multiplex probes P2-like 1, P2-like 2, P2-like group A and individual PCR probe GI2. P2L assignment; positive PCR amplicons from multiplex probes P2-like 1, P2-like 2. bConfluent lysis when spot tested with ~106 pfu φX216. cφX216 source strain. d1026b φ52237-like prophage is split into two segments and likely non-functional [15]. eP2-like prophage group cannot be determined based on PCR results. May be P2L-A or φ52237-like. fφK96243 prophage (group P2-A) located at GI2 [9]. gEncodes the predicted prophage PI-S13-1 (group P2-A) [88]. hP2-like prophage group cannot be assigned based on PCR results. May be P2L or φ52237-like. IND, GI2 probe results not determined. jNon-confluent lysis / individual plaques when spot tested with ~ 106 pfu φX216.